Cygnus nicotine patch
Executive Summary
NDA for the transdermal patch developed for Pharmacia Leo, makers of Nicorette chewing gum, will be filed in "a matter of weeks," President and CEO David de Weese told a Robertson Stephens Medical Conference in New York City Nov. 27. De Weese stressed that the clinical endpoint of Phase III studies of the patch was "total abstenince" verified by checking patient respiration, saliva, and serum. "When looking at clinical data from the competition, I would ask you to keep that in mind," he added. Elan filed an NDA for Nicolan in August 1989, and Marion Merrell Dow expects to file an NDA for Alza's transdermal nicotine in the first quarter of 1990 ("The Pink Sheet" Oct. 29, p. 16).
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.